Clinical trials: Severe Pneumonia
Pneumonia
Efficacy of Single Versus Double Dose of Oral Amoxicillin for Non-Severe Pneumonia in Children
The World Health Organization's (WHO) standard case management strategy for reducing acute respiratory infection (ARI) related mortality recommends oral cotrimoxazole and oral amoxicillin as first line drugs for the treatment of…
- Trial name
- NCT00130013
- Testing
- Oral Amoxicillin
- Where
- Pakistan
- Volunteers
- 900 people
- Sponsor
- ARI Research Cell
Respiration, Artificial, COVID-19
Healthcare-associated Infections in Severe COVID-19 During 2020
In patients who develop ARDS due to SARS-CoV-2 (CARDS), a longer duration of invasive mechanical ventilation (IMV) and ICU stay has been reported compared to ARDS not associated with SARS-CoV-2.
- Conditions
- Respiration, Artificial, COVID-19, Health Care Associated Infection
- Trial name
- COVIACS (NCT04819165)
- Testing
- COVID-19
- Where
- Argentina
- Volunteers
- 252 people
- Sponsor
- Sanatorio Anchorena San Martin
COVID-19, Bacterial Infections
Incidence of Colonization by Multidrug-resistant Organisms in Mechanically Ventilated Patients With Severe COVID-19
Retrospective single-center cohort study to evaluate the incidence of colonization by multidrug-resistant organisms (MDRO) in mechanically ventilated patients admitted to a large intensive care unit (ICU) for severe acute…
- Conditions
- COVID-19, Bacterial Infections, Colonization, Asymptomatic
- Trial name
- MDR_in_Fiera (NCT05293418)
- Testing
- data collection
- Where
- Italy
- Volunteers
- 435 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Pulmonary Fibrosis, COVID-19
Pulmonary Fibrosis After Severe COVID-19 Pneumonia
Patients discharged after hospitalization for COVID-19 pneumonia were retrospectively selected by radiologically established criteria that at admission presented at chest computed tomography (CT) (i) normal lung parenchyma <50%…
- Trial name
- SPIFFERO (NCT06423560)
- Testing
- Computed tomography
- Where
- Italy
- Volunteers
- 61 people
- Sponsor
- IRCCS San Raffaele
COVID-19
Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults
Phase 2, randomized, open-label study to evaluate the safety and efficacy of maraviroc, favipiravir, and both drugs administered along with currently used therapy in hospitalized patients with pulmonary SARS-CoV-2 (Severe Acute…
- Trial name
- COMVIVIR (NCT04475991)
- Testing
- Maraviroc + Currently used therapy, Curently used therapy for COVID-19 non-critical patients, Favipiravir + Currently used therapy
- Where
- Mexico
- Volunteers
- 19 people
- Sponsor
- Hospital General de México Dr. Eduardo Liceaga
COVID 19
Cognitive and Psychological Disorders After Severe COVID-19 Infection
As COVID-19 pandemic is still ongoing, patients follow-up begins to reveal cognitive and psychological disorders. There are not yet well described, neither their physiopathology.
- Trial name
- NEUROCOG-COVID (NCT04937582)
- Testing
- Cognitive assessment, Imaging, Routine care
- Where
- France
- Volunteers
- 76 people
- Sponsor
- Central Hospital, Nancy, France
Chronic Graft-versus-host-disease
Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease
Chronic graft-versus-host disease (cGVHD) affects 30 to 70% of Allogeneic Hematopoietic Cell Transplantation, decreases the quality of life, and increases mortality.
- Trial name
- NCT05348096
- Testing
- Low-dose ibrutinib
- Where
- Mexico
- Volunteers
- 13 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
COVID-19
Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention
The purpose of the study is to assess safety and immunogenicity of heterologous booster vaccine containing combination of AZD1222 and rAd26-S (one of components of Gam-COVID-Vac vaccine) in adult subjects aged ≥ 18 years old to…
- Trial name
- NCT04686773
- Testing
- AZD1222, rAd26-S
- Where
- Azerbaijan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- R-Pharm
COVID-19, Acute Kidney Injury
Applying Artificial Intelligence to Identify Subphenotypes of Acute Kidney Injury in Mexican Patients With Severe COVID-19
The goal of this observational study was to identify subphenotypes of acute kidney injury patients with COVID-19, and the investigators analyzed their impact on mortality.
- Trial name
- IA-COVAKI (NCT06471101)
- Testing
- clusters
- Where
- Mexico
- Volunteers
- 2,934 people
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
Hospital Acquired Pneumonia
Dexamethasone for Treating Severe Hospital-acquired Pneumonia in Critically Ill Patients With a Proinflammatory Phenotype
Determine the efficacy of dexamethasone plus standard of care (SOC) as compared to placebo plus SOC for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype; It's an…
- Trial name
- HAP-DEX (NCT06269900)
- Testing
- Dexamethasone
- Where
- 34 sites in France, Greece and 1 more
- Volunteers
- 450 people
- Sponsor
- Nantes University Hospital
COVID-19
ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease
Albertans with COVID-19 are at risk of deteriorating and developing severe illness. Those over age 40 or with co-morbid illness, and likely those who are immune suppressed, are at highest risk.
- Trial name
- NCT04329611
- Testing
- Hydroxychloroquine
- Where
- 2 sites in Canada
- Volunteers
- 148 people
- Sponsor
- Dr. Michael Hill
Severe COVID-19
Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO)
This phase 2b clinical study will enroll adult subjects of both sexes with ARDS due to COVID-19 necessitating invasive mechanical ventilation.
- Trial name
- IPCO (NCT04712344)
- Testing
- COVID-19 convalescent plasma
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
COVID
Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19
The disease caused by the SARS-CoV-2 virus is a viral disease that infects the lungs, producing flu-like symptoms. Elderly infected patients and/or those with co-morbidities may suffer from acute respiratory distress syndrome due…
- Trial name
- MESCEL-COVID19 (NCT04366271)
- Testing
- Mesenchymal cells, Standard of care
- Where
- 6 sites in Spain
- Sponsor
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Daily Regimen of Tenofovir/Emtricitabine as Prevention for COVID-19 in Health Care Personnel in Colombia
Effectiveness of the use of Tenofovir/Emtricitabine in addition to personal protective equipment for the prevention of the transmission of SARS-COV-2 to health care personnel. A Randomized Clinical Trial.
- Trial name
- NCT04519125
- Testing
- Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE)
- Volunteers
- 950 people, healthy volunteers welcome
- Sponsor
- Hospital Universitario San Ignacio
COVID-19 Pneumonia
The Role of High Dose Co-trimoxazole in Severe Covid-19 Patients
Coronavirus Disease 19 (COVID-19) is a worldwide pandemic and a major global health concern which is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04884490
- Testing
- Co-trimoxazole
- Where
- Bangladesh
- Volunteers
- 94 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
COVID 19, Pulmonary Disease
COVID-19 Search in Conjunctival Cells
The patients enrolled in this study will be all patients entering triage with suspicion of SARS-CoV2. Planned activities are required by the nasopharyngeal swab in parallel with the analysis of the conjunctival swab to identify…
- Trial name
- COVID-T (NCT04364594)
- Testing
- conjunctival swab
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2019-nCoV Severe Pneumonia
The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia
At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of different hormone doses in the…
- Trial name
- NCT04263402
- Testing
- Methylprednisolone
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital
COVID-19 Infection
Clinical Characteristics and Prognostic Factors of Patients With COVID-19 (Coronavirus Disease 2019)
This is a multicenter, non-interventional, retrospective study using data captured in the EHRs (Electronic Health Records) of the participating hospital sites to determine factors that predict disease prognosis and outcomes in…
- Trial name
- NCT04569851
- Where
- 2 sites in Spain
- Volunteers
- 100,000 people
- Sponsor
- Savana Research
Severe COVID-19 Pneumonia
A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019（COVID-19）Pneumonia
The study is a Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects with Severe Corona Virus Disease 2019（COVID-19）Pneumonia.
- Trial name
- NCT04880694
- Testing
- STC3141
- Where
- 4 sites in Belgium
- Volunteers
- 25 people
- Sponsor
- Grand Medical Pty Ltd.
Deep Venous Thrombosis
Deep Venous Thrombosis in Non-severe COVID-19 Patients Hospitalized for a Neurovascular Pathology
Severe SARS-CoV-2 infection, responsible of COVID-19, is accompanied by many venous thromboembolic events. Antithrombotic treatment is the cornerstone of management of many neurovascular diseases (NVDs) and the benefit-risk ratio…
- Trial name
- VT-Covid-19 (NCT04452422)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.